about
Cannabidiol in humans-the quest for therapeutic targetsProlactin in multiple sclerosis.Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial.Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia.Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine.Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies.Relationship between insight into cognition, extrapyramidal symptoms and mental illness in schizophrenia.Evidence that the reward attenuating effect of the D1-like antagonist, SCH-23390, is not mediated by its agonist action at the 5-HT2c receptors.Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients
P50
Q34657897-0EF8822C-06F0-42C8-BA9D-A42B4BA2CBDEQ38039054-D994CEC9-8031-43F8-B600-D06D30800ADAQ42846112-C186E2AB-E40C-4A4F-ADAC-A522C7C5FC48Q42952834-7F1D7690-46D6-4EA5-B9CF-D406DA286963Q42982683-01F4CEB1-D10E-4FA8-86AC-D13A38F96118Q43063027-346E4409-EE6F-4242-97F8-D73F91A02971Q51811902-F10470D5-6E0E-4116-920D-618EF4E590B9Q51898536-397D76A6-1161-4186-A5FF-247698BBC607Q84974665-591B36BC-EAAA-4271-AF53-EF29DF6969CE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Simon Zhornitsky
@ast
Simon Zhornitsky
@en
Simon Zhornitsky
@es
Simon Zhornitsky
@nl
Simon Zhornitsky
@sl
type
label
Simon Zhornitsky
@ast
Simon Zhornitsky
@en
Simon Zhornitsky
@es
Simon Zhornitsky
@nl
Simon Zhornitsky
@sl
prefLabel
Simon Zhornitsky
@ast
Simon Zhornitsky
@en
Simon Zhornitsky
@es
Simon Zhornitsky
@nl
Simon Zhornitsky
@sl
P106
P1153
36081492200
P21
P31
P496
0000-0003-2024-7062